

Novo Nordisk



Novo Nordisk at a glance

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care.

This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.

life-changing careers[®]



PRODUCTS MARKETED IN
180 COUNTRIES



AFFILIATES IN COUNTRIES **75**



R&D CENTRES

IN CHINA, DENMARK,
INDIA AND US



OBESITY



EMPLOYS APPROXIMATELY

41,000 PEOPLE

DIABETES

DKK **107.9**
BILLION
IN TOTAL REVENUE



APPROXIMATELY

230,000
SHAREHOLDERS

**STRATEGIC
PRODUCTION SITES**

IN BRAZIL, CHINA, DENMARK,
FRANCE AND US



GROWTH
DISORDERS

SUPPLIER OF MORE THAN
**HALF OF THE
WORLD'S INSULIN**




HAEMOPHILIA

26,800,000
PEOPLE USE OUR PRODUCTS

TBL is how we do business

Integrated into the Novo Nordisk Way and our bylaws




The Company strives to conduct its activities in a financially, environmentally, and socially responsible way.

*"As most companies, we have a **financial** bottom line but we also have a **social** and an **environmental** bottom line. Because if you look at your business in a long enough time perspective, then social and environmental issues become financial issues."*

Lars Rebien Sørensen,
President and Chief Executive Officer

Novo Nordisk first focused at emissions from energy used at production sites



- 1 Increased production efficiency
- 2 Increased energy efficiency
- 3 Renewable energy



Energy efficiency



Denmark, Japan
China



Bio-natural gas
in Denmark




Biomass steam Kal
(2019)



Solar power in US
(2018-2019)

Now the focus is on the full value chain



How to manage global complexity

RE 100
By 2020

